Skip to content

Chris Seeger Appointed to the Humira MDL Executive Committee

Seeger Weiss founding partner, Chris Seeger, has been appointed to the MDL Executive Committee of pending antitrust litigation against drug maker AbbVie for the company’s action regarding popular immune drug, Humira. A number of lawsuits against AbbVie and other pharmaceutical companies have been brought by insurance clients and other end-payers due to accusations that the […]

June 7, 2019

Chris Seeger headshot

Seeger Weiss founding partner, Chris Seeger, has been appointed to the MDL Executive Committee of pending antitrust litigation against drug maker AbbVie for the company’s action regarding popular immune drug, Humira.

A number of lawsuits against AbbVie and other pharmaceutical companies have been brought by insurance clients and other end-payers due to accusations that the companies engaged in unfair competitive acts regarding Humira and its related patents. These cases have been consolidated into multidistrict litigation (MDL) in the U.S. District Court for the Northern District of Illinois under Judge Manish S. Shah.

Judge Shah has appointed Seeger Weiss founding partner, Chris Seeger to the Executive Committee for the Humira MDL. The MDL Executive Committee is comprised of nine attorneys which includes three co-lead counsels from New York, California and Massachusetts and six plaintiff’s executive committee members from Louisiana, New York, Pennsylvania, and California.

The lawsuits claim that AbbVie engaged in improper anti-competitive action to protect its market exclusivity of autoimmune drug Humira. The lawsuits have been brought by insurance and managed care payers who may have been improperly forced to pay higher costs for Humira versus similar medications which were blocked from the U.S. market.

Humira is a flagship drug of AbbVie and brings the company over $20 billion per year in revenue. It is used for a number of autoimmune disorders including Rheumatoid Arthritis and is the best-selling medication of its type. Outside of the U.S., Humira faces competition from biosimilar medications but AbbVie has been successful in preventing U.S. competition with a web of over 100 patents that surround the medication.

Related News

March 14, 2023
Seeger Weiss Obtains $10 Million Settlement In Whistleblower Lawsuit Against Medical Device Company Stimwave

New York, NY– Today, the Department of Justice announced a $10 million settlement with Florida-based medical device company Stimwave, and a criminal indictment charging former CEO Laura Perryman in connection with a scheme to create and sell a non-functioning dummy medical device for implantation into patients suffering from chronic pain.  The scheme resulted in millions […]

Read More
February 28, 2023
Eleven Seeger Weiss Partners Selected For Lawdragon 500 Leading Plaintiff Consumer Lawyers List

Seeger Weiss is proud to announce that eleven of the firm’s partners were selected for Lawdragon 500 Leading Plaintiff Consumer Lawyers list for 2023. This list celebrates attorneys who are “tenacious advocates and dogged pursuers of justice,” a description fitting for these accomplished members of the Seeger Weiss team. Founding partners Chris Seeger and Stephen […]

Read More
February 9, 2023
Former NFL Players File Class Action Lawsuit Against NFL Disability Plans, Board, Commissioner Roger Goodell For Systemic Bias Against Disabled Players

New data suggest “neutral” NFL-hired doctors who deny more claims receive higher compensation. Baltimore, MD – Former NFL players today filed a class action lawsuit against The NFL Player Disability & Survivor Benefit Plan and NFL Player Disability & Neurocognitive Benefits Plan (the Plan), the Disability Board that administers the Plan, and each of the […]

Read More